Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/LSD/Interpersonal Functioning & Social Connectedness

LSD for Interpersonal Functioning & Social Connectedness

27 papers and 1 clinical trial exploring lsd as a treatment for interpersonal functioning & social connectedness.

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM120 have reignited clinical development.

Full LSD profile
IndicationApproximately 300 million individuals worldwide experience issues with social connectedness and interpersonal relations.

Interpersonal Functioning & Social Connectedness

Research on psychedelics highlights their potential to enhance interpersonal functioning and social connectedness, particularly through compounds such as psilocybin and MDMA. These compounds may facilitate therapeutic outcomes in various mental health disorders by fostering emotional connectivity and empathy among individuals.

Full Interpersonal Functioning & Social Connectedness profile

Academic Research

27 papers
Open Accessmeta

Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task

This meta-analysis (s=5, n=158) of classic psychedelic effects on empathy using the Multifaceted Empathy Test (MET) finds significant enhancement of explicit and implicit emotional empathy, with no effect on cognitive empathy. The analysis covers studies up to November 2023 examining LSD, psilocybin, and ayahuasca.

Published
October 18, 2024
Journal
Scientific Reports
Authors
Olami, A., Peled-Avron, L.
Paywallindividual

Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey

This online survey (n=233) of autistic participants with high autism quotient scores examines their experiences with psychedelic drugs and perceived changes attributed to their most 'impactful' psychedelic experience. It finds that the majority of participants reported reductions in psychological distress (82%) and social anxiety (78%), and increases in social engagement (70%), while 20% reported undesirable effects such as increased anxiety.

Published
October 5, 2024
Journal
Psychopharmacology
Authors
Stroud, J., Rice, C., Orsini, A., Schlosser, M., Lee, J., Mandy, W., Kamboj, S. K.
Open Accessindividual

Trauma Under Psychedelics: MDMA Shows Protective Effects During the Peritraumatic Period

In a naturalistic cohort of 772 survivors of the October 7 Supernova festival attack, participants who were under the influence of MDMA during the trauma reported lower psychological distress, fewer PTSD symptoms, greater social interaction and better sleep in the one to four months post-attack compared with those who were sober, whereas cannabis and/or alcohol use was associated with worse outcomes. These novel findings suggest a putative protective role for MDMA during the peritraumatic period and warrant mechanistic and longitudinal investigation.

Published
March 31, 2024
Journal
Biorxiv
Authors
Netzer, O., Magal, N., Stern, Y., Polinsky, T., Gross, R., Admon, R., Salomon, R.
Open Accessindividual

Effects of Psychedelic Microdosing versus Conventional ADHD Medication Use on Emotion Regulation, Empathy, and ADHD Symptoms in Adults with severe ADHD symptoms: A Naturalistic Prospective Comparison Study

Two naturalistic prospective studies in adults with severe ADHD symptoms found that psychedelic microdosing was associated with improved emotion regulation and a reduction in ADHD symptom severity over four weeks, with a persistent benefit on expressive suppression when compared with controls and conventional medication. There was no robust evidence that microdosing improved empathy.

Published
February 14, 2024
Journal
European Psychiatry
Authors
Haijen, E. C. H. M., Hurks, P. P. M., Kuypers, K. P. C.
Open Accessmeta

Microdosing psychedelics: Current evidence from controlled studies

This systematic review (s=14) compiles double-blind, placebo-controlled studies on microdosing LSD (5-20μg) under laboratory conditions. It reports that acute low doses of LSD affect blood pressure, sleep, neural connectivity, mood, social cognition, and perceptions of pain and time, with noticeable effects at 10-20 μg but not at 5μg. While no serious adverse effects were noted, repeated microdosing did not significantly change mood or cognition.

Published
January 26, 2024
Journal
Biological Psychiatry
Authors
Murphy, R., Muthukumaraswamy, S., De Wit, H.
Open Accessmeta

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences

In a prospective convenience sample (N = 698; n = 27 co‑users), co‑use of a low dose of MDMA with psilocybin/LSD was associated with reduced overall challenging experiences—especially grief and fear—and increased self‑compassion, love and gratitude, while mystical‑type experiences and compassion were unchanged. The authors caution the small, non‑experimental convenience sample and recommend controlled dose–response studies to assess safety and therapeutic potential.

Published
August 22, 2023
Journal
Scientific Reports
Authors
Zeifman, R. J., Kettner, H., Pagni, B. A., Mallard, A., Roberts, D. E., Erritzoe, D., Ross, S., Carhart-Harris, R. L.

Clinical Trials

1 trial
Unknown statusPhase I/II

The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality

This double-blind, placebo-controlled crossover trial (n=60) investigates the effects of LSD on neural synchrony, prosocial behavior, and relationship quality in healthy romantic couples.

Started
January 1, 2023
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT05670184

Explore further

Search all LSD papers Search all Interpersonal Functioning & Social Connectedness trials Full LSD profile Full Interpersonal Functioning & Social Connectedness profile